Ultrasound‑targeted microbubble destruction‑mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function

Shi,Chunying; Zhang,Yu; Yang,Haichao; Dong,Tianxiu; Chen,Yaodong; Xu,Yutong; Yang,Xiuhua; Liu,Pengfei

doi:10.3892/etm.2017.5421

Ultrasound‑targeted microbubble destruction‑mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function

Authors:
- Chunying Shi
- Yu Zhang
- Haichao Yang
- Tianxiu Dong
- Yaodong Chen
- Yutong Xu
- Xiuhua Yang
- Pengfei Liu
View Affiliations

Affiliations: Department of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Heilongjiang, Harbin 150001, P.R. China, MRI Department, The First Affiliated Hospital of Harbin Medical University, Heilongjiang, Harbin 150001, P.R. China
Published online on: November 1, 2017 https://doi.org/10.3892/etm.2017.5421
Pages: 31-38
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of Forkhead family transcription factor P3 (Foxp3) knockdown on the function of cluster of differentiation (CD)4+CD25+ regulatory T cell (Tregs) and the tumor growth of a hepatocellular carcinoma (HCC) mouse model. CD4+CD25+ Tregs and CD4+CD25‑ T cells were sorted from peripheral blood mononuclear cells (PBMCs) of patients with HCC. Then, ultrasound‑targeted microbubble destruction (UTMD)‑mediated Foxp3‑microRNA (miRNA) was transfected into Tregs. Subsequently, CD4+CD25‑ T cells were co‑cultured with PBMC and Tregs without Foxp3‑miRNA (Foxp3+Tregs) or Tregs with Foxp3‑miRNA (Foxp3‑Tregs) and the proliferation‑inhibition ratio of CD4+CD25‑ T cells was detected using a Cell Counting Kit‑8. Additionally, HCC mice were treated with UTMD‑mediated Foxp3‑shRNA, the tumor volume was calculated and the content of CD4+ and CD25+ T cells in the blood were detected using flow cytometry. The content of interferon‑γ (IFN‑γ), interleukin (IL)‑2, IL‑10, transforming growth factor‑β (TGF‑β) and vascular endothelial growth factor (VEGF) in cultural supernatant and serum were detected by ELISA analysis. Foxp3‑Tregs significantly reduced the inhibition effect of Foxp3+Tregs on the proliferation of CD4+CD25‑ T cells (P<0.01). The content of IFN‑γ and IL‑2 significantly increased, while IL‑10 and TGF‑β significantly decreased in the co‑cultured system of Foxp3‑Tregs compared with the co‑cultured system of Foxp3+Tregs (P<0.01). Following treatment with Foxp3‑shRNA, the average tumor volume, ratio of Tregs/CD4+ T cells and level of IL‑10, TGF‑β and VEGF significantly decreased, however, the level of IFN‑γ and IL‑2 significantly increased compared with un‑treated HCC mice (P<0.05). Foxp3 knockdown may suppress the tumor growth of HCC mice through relieving the immunosuppressive function of Tregs.

View Figures

View References

1	Han KH, Kudo M, Ye SL, Choi JY, Poon RP, Seong J, Park JW, Ichida T, Chung JW, Chow P and Cheng AL: Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 81 Suppl 1:S158–S164. 2011. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
4	Pardee AD and Butterfield LH: Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology. 1:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ganss R and Hanahan D: Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58:4673–4681. 1998.PubMed/NCBI
6	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
7	Linehan DC and Goedegebuure PS: CD25+ CD4+ regulatory T-cells in cancer. Immunol Res. 32:155–168. 2005. View Article : Google Scholar : PubMed/NCBI
8	von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol. 6:338–344. 2005. View Article : Google Scholar : PubMed/NCBI
9	Fontenot JD and Rudensky AY: A well adapted regulatory contrivance: Rregulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 6:331–337. 2005. View Article : Google Scholar : PubMed/NCBI
10	Tsai BY, Suen JL and Chiang BL: Lentiviral-mediated Foxp3 RNAi suppresses tumor growth of regulatory T cell-like leukemia in a murine tumor model. Gene Ther. 17:972–979. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA and Aoyagi Y: Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 45:254–262. 2006. View Article : Google Scholar : PubMed/NCBI
13	Walton CB, Anderson CD, Boulay R and Shohet RV: Introduction to the ultrasound targeted microbubble destruction technique. J Vis Exp. 52:e29632011.
14	Geis NA, Katus HA and Bekeredjian R: Microbubbles as a vehicle for gene and drug delivery: Current clinical implications and future perspectives. Curr Pharm Design. 18:2166–2183. 2012. View Article : Google Scholar
15	Li YS, Davidson E, Reid CN and McHale AP: Optimising ultrasound-mediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: Potential applications for gene therapy of cancer. Cancer Lett. 273:62–69. 2009. View Article : Google Scholar : PubMed/NCBI
16	Fujii H, Sun Z, Li SH, Wu J, Fazel S, Weisel RD, Rakowski H, Lindner J and Li RK: Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc Imaging. 2:869–879. 2009. View Article : Google Scholar : PubMed/NCBI
17	Carson AR, McTiernan CF, Lavery L, Hodnick A, Grata M, Leng X, Wang J, Chen X, Modzelewski RA and Villanueva FS: Gene therapy of carcinoma using ultrasound-targeted microbubble destruction. Ultrasound Med Biol. 37:393–402. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF and Lu SN: Validation of the 7th edition TNM staging system for hepatocellular carcinoma: An analysis of 8,828 patients in a single medical center. Dig Dis Sci. 58:2721–2728. 2013. View Article : Google Scholar : PubMed/NCBI
19	Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV and Weinberg MS: Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther. 24:488–498. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ewert KK, Ahmad A, Bouxsein NF, Evans HM and Safinya CR: Non-viral gene delivery with cationic liposome-DNA complexesGene Therapy Protocols. Springer; New York, NY: pp. 159–175. 2008, View Article : Google Scholar
21	Karmali PP and Chaudhuri A: Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises. Med Res Rev. 27:696–722. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L and Chen HS: Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol. 36:841–848. 2010.PubMed/NCBI
23	Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG and Rudensky AY: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 22:329–341. 2005. View Article : Google Scholar : PubMed/NCBI
24	Dieckmann D, Plottner H, Berchtold S, Berger T and Schuler G: Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med. 193:1303–1310. 2001. View Article : Google Scholar : PubMed/NCBI
25	Shevach EM: CD4+ CD25+ suppressor T cells: More questions than answers. Nature Rev Immunol. 2:389–400. 2002.
26	Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
27	Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T and Sakaguchi S: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 446:685–689. 2007. View Article : Google Scholar : PubMed/NCBI
28	Pandiyan P, Zheng L, Ishihara S, Reed J and Lenardo MJ: CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 8:1353–1362. 2007. View Article : Google Scholar : PubMed/NCBI
29	Nair S, Boczkowski D, Fassnacht M, Pisetsky D and Gilboa E: Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67:371–380. 2007. View Article : Google Scholar : PubMed/NCBI
30	Nishikawa H and Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
31	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI